<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="48">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04531748</url>
  </required_header>
  <id_info>
    <org_study_id>20-842</org_study_id>
    <nct_id>NCT04531748</nct_id>
  </id_info>
  <brief_title>Selective Estrogen Modulation and Melatonin in Early COVID-19</brief_title>
  <acronym>SENTINEL</acronym>
  <official_title>Selective Estrogen Modulation and Melatonin in Early COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Reena Mehra, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized, double-blind, controlled clinical trial to evaluate the effects
      of toremifene and/or melatonin in adults with mild COVID-19.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized, double-blind, controlled clinical trial to evaluate the effects
      of a 14 day intervention of toremifene plus melatonin or melatonin in adults with mild
      COVID-19.

      The study will evaluate the progression of clinical signs and symptoms (fever, dyspnea,
      cough, fatigue daily score) and any adverse outcomes in comparison to placebo for 30 days.

      The successful completion of this project offers high potential to identify effective
      treatment (e.g., toremifene plus melatonin and/or melatonin) rapidly for patients with early
      COVID-19 and to provide, important, fundamental mechanistic insights.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The Medical Safety Officer will not be blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Peak increase in COVID-19 Sign and Symptom score</measure>
    <time_frame>Screening to 28 days</time_frame>
    <description>Score total of 0-12 assessed daily. Each category based on severity of symptoms of Cough, Shortness of breath, Fatigue/tiredness and daily temperature on a rating scale of 0-3.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nadir Oxygen Saturation</measure>
    <time_frame>Day 1 through day 14</time_frame>
    <description>Daily mean values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Heart Rate</measure>
    <time_frame>Day 1 through day 14</time_frame>
    <description>Daily mean values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to COVID-19 Sign and Symptom score resolution</measure>
    <time_frame>Screening to 28 days</time_frame>
    <description>Score total of 0-12 assessed daily. Each category based on severity of symptoms of Cough, Shortness of breath, Fatigue/tiredness and daily temperature on a rating scale of 0-3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to WHO 7-point ordinal scale score of 3 or higher</measure>
    <time_frame>Day 1 to Day 30</time_frame>
    <description>not hospitalized, no limitation of activities (or resumption of normal activity)
not hospitalized but limitation on activities
hospitalized, not requiring supplemental oxygen
hospitalized, requiring supplemental oxygen (low-flow, e.g., nasal prong)
hospitalized, requiring non-invasive ventilation and/or high-flow oxygen
hospitalized, on invasive ventilation or ECMO
death</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">390</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Toremifene + Melatonin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>100mg oral Melatonin on Days 1 &amp; 2 (40mg in the morning and 60mg in the evening), 60 mg on Days 3-14, (20mg in the morning and 40mg in the evening).
60mg oral toremifene daily days 1-14.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Melatonin + Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>100mg oral Melatonin on Days 1 &amp; 2 (40mg in the morning and 60mg in the evening) and 60 mg on Days 3-14, (20mg in the morning and 40mg in the evening).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral placebo will be used with the same number and appearance to the pills as the interventions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Toremifene</intervention_name>
    <description>Participants will be instructed to take 60mg of oral toremifene capsule daily, 30 minutes before bedtime.</description>
    <arm_group_label>Toremifene + Melatonin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melatonin</intervention_name>
    <description>Participants will be instructed to take the pills orally around the same time in the morning and 30 minutes prior to bedtime in the evening.</description>
    <arm_group_label>Melatonin + Placebo</arm_group_label>
    <arm_group_label>Toremifene + Melatonin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral placebo will be used with the same number and appearance to the pills as the interventions.</description>
    <arm_group_label>Melatonin + Placebo</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical testing positive for SARS-Cov-2 by standard RT-PCR or equivalent test

          -  Willing and able to give informed consent for participation in the study and agrees
             with the study and its conduct

          -  Age&gt;18 years

          -  Fluency in English or Spanish language, functional literacy

          -  Able to swallow pills

          -  COVID-19 Daily Sign and Symptom score of 2-8

        Exclusion Criteria:

          -  History of deep venous thrombosis or pulmonary embolism

          -  Hypercoagulable disorders (e.g. lupus anticoagulant, deficiency of protein C or S)

          -  Embolic stroke

          -  Liver disease

          -  History of endometrial cancer

          -  Menopausal hormone therapy or oral, injectable or transdermal contraceptives

          -  Depression which is not optimally treated (assessed via medical record and patient
             will be asked if she/he feels that depression is optimally treated)

          -  Medications which prolong the QT interval (e.g. hydroxychloroquine or azithromycin) or
             those with long QT syndrome (heritable or acquired). Examples of other medications
             which prolong the QT interval include: Agents generally accepted to prolong QT
             interval include Class 1A (e.g., quinidine, procainamide, disopyramide) and Class III
             (e.g., amiodarone, sotalol, ibutilide, dofetilide) antiarrhythmics; certain
             antipsychotics (e.g., thioridazine, haloperidol); certain antidepressants (e.g.,
             venlafaxine, amitriptyline); certain antibiotics (e.g., erythromycin, clarithromycin,
             levofloxacin, ofloxacin); and certain anti-emetics (e.g., ondansetron, granisetron)
             (Please refer to Appendix for detailed list of medications)

          -  Inability to participate in follow up assessment

          -  Dementia/cognitive dysfunction

          -  Pregnancy (pregnancy testing will be performed to determine eligibility)

          -  Breastfeeding

          -  Participating in other COVID-19 trials

          -  Immunodeficiency (including HIV, Hepatitis C, bone marrow transplant history, on
             immunosuppressant medications)

          -  Current hospitalization

          -  Seizure disorder

          -  History of rheumatoid arthritis

          -  Heart failure (NYHA Class III or IV)

          -  Current diagnosis of renal insufficiency/failure

          -  QTc &gt;470ms per 12-lead ECG

          -  Calcium &gt;10.2mg/dL

          -  AST or ALT &gt; 2x upper limit of normal (ULN)

          -  D-dimer &gt;= 1000 u/L

          -  Estimated glomerular filtration rate (eGFR) &lt;60 mL/min/1.73 m2

          -  On other treatment(s) for COVID-19 (e.g. hydroxychloroquine, remdesivir)

          -  Anticoagulant medications (e.g. coumadin, glycoprotein IIa/IIIb inhibitors)

          -  Clinical signs of severe or critical severity of COVID-19 (e.g. shortness of breath at
             rest, Respiratory rate ≥ 30 per minute, heart rate ≥ 125 per minute, SpO2 ≤ 93% on
             room air)

          -  Use of supplemental oxygen

          -  Moderate to severe pulmonary disease up to PI discretion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reena Mehra, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Samantha Wells</last_name>
    <phone>3162152759</phone>
    <email>wellss@ccf.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kylie Phillips</last_name>
    <phone>2164451593</phone>
    <email>philik3@ccf.org</email>
  </overall_contact_backup>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 27, 2020</study_first_submitted>
  <study_first_submitted_qc>August 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2020</study_first_posted>
  <last_update_submitted>August 27, 2020</last_update_submitted>
  <last_update_submitted_qc>August 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>The Cleveland Clinic</investigator_affiliation>
    <investigator_full_name>Reena Mehra, MD</investigator_full_name>
    <investigator_title>Director, Sleep Disorders Research, Neurological Institute</investigator_title>
  </responsible_party>
  <keyword>covid19</keyword>
  <keyword>coronavirus</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Toremifene</mesh_term>
    <mesh_term>Melatonin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

